Investing.comCodex · 实盘不做把握 4/10
北京时间·🕒 发布 07-22 20:04:33时区推断·⟳ 抓取 07-22 20:06:28·⚡ 决策 07-23 08:43:24 +12h36m·96.5 天前
LB Pharmaceuticals将LB-102精神分裂症三期数据读出提前至2027年上半年
NOVA-2入组快于预期，使三期顶线数据读出从2027年下半年提前至2027年上半年。
📄 原文Investing.com↗ 原文
LB Pharmaceuticals accelerates schizophrenia trial timeline
Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven? NEW YORK - LB Pharmaceuticals Inc (NASDAQ…
不做 LB Pharmaceuticals（LBRX.US）
只是三期读出时间提前，不是疗效成功、获批或商业化收入事件；短期交易edge不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-22 · 扩散 low · price-in 风险 medium ↗
关键理由
- NOVA-2入组快于预期，使三期顶线数据读出从2027年下半年提前至2027年上半年。
- 公司预计现金可支持运营至2029年二季度，降低近期融资压力。
- 当前不是疗效数据读出、监管批准或商业化里程碑。
主要风险
- 临床时间线提前通常是中低强度催化，核心二元风险仍在2027年三期结果。
- LB-102仍为在研药物，当前无法形成近期收入或利润增量。
原文全文
展开原文 · 1,685 字
Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven?
NEW YORK - LB Pharmaceuticals Inc (NASDAQ:LBRX) announced today that it expects to report results from its Phase 3 NOVA-2 clinical trial of LB-102 in schizophrenia patients in the first half of 2027, ahead of its previous guidance of the second half of 2027, according to a press release statement.
The company said enrollment in the trial has progressed faster than anticipated. LB Pharmaceuticals plans to schedule a pre-NDA meeting with the FDA in the second half of 2027 following the trial results.
NOVA-2 is a multi-center, randomized, double-blind, placebo-controlled trial designed to enroll approximately 460 patients across 25 sites in the U.S. to evaluate the efficacy and safety of LB-102 for schizophrenia treatment.
"Enrollment in our pivotal Phase 3 NOVA-2 trial has been more rapid than we expected," said Heather Turner, Chief Executive Officer of LB Pharmaceuticals.
The company stated it has a cash runway expected to fund operations into the second quarter of 2029. LB Pharmaceuticals also expects topline data from its Phase 2 ILLUMINATE-1 trial of LB-102 in bipolar depression in the first quarter of 2028, and from a Phase 2 trial of LB-102 in adjunctive major depressive disorder in the first half of 2029.
LB-102 is an investigational oral small molecule administered once daily. The company reported positive data from a Phase 2 trial in patients with acute schizophrenia in early 2025, which showed statistically significant benefit versus placebo at all doses studied.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
NEW YORK - LB Pharmaceuticals Inc (NASDAQ:LBRX) announced today that it expects to report results from its Phase 3 NOVA-2 clinical trial of LB-102 in schizophrenia patients in the first half of 2027, ahead of its previous guidance of the second half of 2027, according to a press release statement.
The company said enrollment in the trial has progressed faster than anticipated. LB Pharmaceuticals plans to schedule a pre-NDA meeting with the FDA in the second half of 2027 following the trial results.
NOVA-2 is a multi-center, randomized, double-blind, placebo-controlled trial designed to enroll approximately 460 patients across 25 sites in the U.S. to evaluate the efficacy and safety of LB-102 for schizophrenia treatment.
"Enrollment in our pivotal Phase 3 NOVA-2 trial has been more rapid than we expected," said Heather Turner, Chief Executive Officer of LB Pharmaceuticals.
The company stated it has a cash runway expected to fund operations into the second quarter of 2029. LB Pharmaceuticals also expects topline data from its Phase 2 ILLUMINATE-1 trial of LB-102 in bipolar depression in the first quarter of 2028, and from a Phase 2 trial of LB-102 in adjunctive major depressive disorder in the first half of 2029.
LB-102 is an investigational oral small molecule administered once daily. The company reported positive data from a Phase 2 trial in patients with acute schizophrenia in early 2025, which showed statistically significant benefit versus placebo at all doses studied.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。